Discovery & Development

Pfizer’s trial of a new medicine for COVID-19, produced with support from the US Department of Energy, could improve access to treatment.

Adoption of organ-on-a-chip technology is on the rise, but misconceptions remain prevalent, says Tomasz Kostrzewski of CN Bio.

Integrating digital technologies into your operations can make all the difference to the formulation process.

An interview with Ken Gruber of Endevica Bio on his work producing a treatment for cachexia, a wasting condition common in late-stage cancer.

A partnership between Gilead Sciences and Georgia State University has tested a new oral antiviral for COVID-19.

Two members of the Drugs for Neglected Diseases initiative lay out how they improved access to Hep C treatment in Southeast Asia and beyond.

How will vaccine and therapeutic makers respond to the new SARS-CoV-2 variant?

Exploring the potential of vaccines for treatment equity.

How can the NLRP3 inflammasome can be exploited to slow the decline associated with Alzheimer's disease?

A drug development journey with origins in the 1950s has finally reached its successful conclusion: a new treatment for lupus.